|
Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial. |
|
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Janssen; Lilly; Novartis; PureTech; Roche/Genentech; SomaNautix |
Research Funding - AstraZeneca |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis; Roche/Genentech |
Other Relationship - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Epizyme; Janssen; Novartis |
|
|
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb |
Research Funding - AstraZeneca (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Ohara Pharmaceutical |
Speakers' Bureau - Chugai Pharma; Novartis; Ohara Pharmaceutical |
|
|
Research Funding - Addmedica (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst) |
|
|
Research Funding - Novartis (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Abbvie; Illumina; Medac |
Consulting or Advisory Role - Abbvie |
Speakers' Bureau - Agilent; Illumina; Medac |
Travel, Accommodations, Expenses - Abbvie; Agilent |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Roche (Inst) |
|
|
|
Consulting or Advisory Role - AstraZeneca; Novartis |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celldex; Chinook Therapeutics; Neoleukin Therapeutics; Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; DNAtrix; Novartis |
Research Funding - Bristol-Myers Squibb; Novartis |